{
  "abstract": "Survodutide is a glucagon receptor/glucagon-like peptide-1 receptor dual agonist under investigation for treating obesity and related diseases. The SYNCHRONIZE-MASLD phase 3, randomized, double-blind, placebo-controlled trial included 216 adults (131 female and 85 male) with obesity (defined as a body mass index ≥30 kg m − 2 or ≥27 kg m − 2 with at least one obesity complication) and at-risk metabolic dysfunction-associated steatotic liver disease (MASLD), defined by MASLD with evidence of liver inflammation and/or fibrosis by noninvasive tests (NITs) or biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH). Participants were randomized (2:1) and treated with once-weekly subcutaneous injections of survodutide 6.0 mg ( n = 146) or placebo ( n = 70). The co-primary endpoints, ≥30% reduction in magnetic resonance imaging-proton density fat fraction (MRI-PDFF)-assessed liver fat content (LFC) and percentage change in body weight (both baseline to week 48), were met. In total, 84.2% of survodutide-treated patients versus 24.3% of placebo-treated patients had ≥30% reduction in LFC using the efficacy estimand ( P < 0.0001; treatment regimen estimand: 68.5% versus 28.6%, respectively; P < 0.0001). Mean percentage change in body weight was −12.2% with survodutide and −1.0% with placebo using the efficacy estimand ( P < 0.0001; treatment regimen estimand: −8.7% versus −1.4%, respectively; P < 0.0001). The most frequently reported adverse events with survodutide were gastrointestinal, commonly occurring during dose escalation, and were generally of mild-to-moderate severity. In adults with obesity and at-risk MASLD, survodutide treatment was statistically and clinically superior to placebo for reductions in MRI-PDFF-assessed LFC and body weight. Limitations included short trial duration (48 weeks) and limited global reach (participants recruited in the United States and Spain).",
  "abstract_shown": true,
  "affiliations": [
    "Geisel School of Medicine at Dartmouth, Hanover, NH, USA. lmkaplan0@gmail.com",
    "The Obesity and Metabolism Institute, Boston, MA, USA. lmkaplan0@gmail.com",
    "Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany",
    "Ulster University, Coleraine, UK",
    "University College Dublin School of Medicine, Dublin, Ireland",
    "McMaster University, Hamilton, Ontario, Canada",
    "University of Toronto, Toronto, Ontario, Canada",
    "Winters Center for Heart Failure Research, Cardiovascular Research Institute, Baylor College of Medicine, Houston, TX, USA",
    "Boehringer Ingelheim International GmbH, Biberach, Germany",
    "Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany",
    "Covenant Metabolic Specialists, LLC, Sarasota and Fort Myers, FL, USA",
    "Optimus U Corp., Miami, FL, USA",
    "Stravitz Sanyal Institute for Liver Disease and Metabolic Health, Division of Gastroenterology, Hepatology and Nutrition, Virginia Commonwealth University School of Medicine, Richmond, VA, USA",
    "Velocity Clinical Research, Gardena, CA, USA",
    "Clinical Trials of Texas, LLC, San Antonio, dba Flourish Research, San Antonio, TX, USA",
    "Washington University School of Medicine, St. Louis, MO, USA",
    "Fleming Island Center for Clinical Research, Fleming Island, FL, USA",
    "Kansas Medical Clinic, Topeka, KS, USA",
    "Excel Medical Clinical Trials, LLC, Boca Raton, dba Flourish Research, Boca Raton, FL, USA",
    "Amel Med, LLC, Georgetown, TX, USA",
    "Ark Clinical Research – PARENT, Long Beach, CA, USA",
    "Louisiana Research Center, LLC, Shreveport, LA, USA",
    "Indiana University, Indianapolis, IN, USA",
    "Biopharma Informatic, LLC, McAllen, TX, USA",
    "Health Awareness, Inc., Jupiter, FL, USA",
    "DSI Research Northridge, LLC, Dayton, OH, USA",
    "University of Iowa Health Care, Iowa City, IA, USA",
    "Velocity Clinical Research, North Hollywood, CA, USA",
    "Velocity Clinical Research, Hallandale Beach, FL, USA",
    "Panax Clinical Research, LLC, Miami Lakes, FL, USA",
    "Ark Clinical Research, Fountain Valley, CA, USA",
    "GI Select Health Research, LLC, Richmond, VA, USA",
    "Catalina Research Institute, Montclair, CA, USA",
    "Velocity Clinical Research, Austin, TX, USA",
    "Velocity Clinical Research, Santa Ana, CA, USA",
    "Velocity Clinical Research, Waco, TX, USA",
    "Accurate Clinical Research, Inc., Richmond, TX, USA",
    "Springfield Clinic, Springfield, IL, USA",
    "Segal Drug Trials, Delray Beach, FL, USA",
    "Nature Coast Clinical Research, Inverness, FL, USA"
  ],
  "article_type": null,
  "arxiv": null,
  "author_total": 46,
  "authors": [
    {
      "affs": [
        0,
        1
      ],
      "name": "Lee M. Kaplan",
      "orcid": "0000-0002-6301-2696"
    },
    {
      "affs": [
        2
      ],
      "name": "Elena Startseva",
      "orcid": "0000-0002-9363-7056"
    },
    {
      "affs": [
        3,
        4
      ],
      "name": "Carel Wynand le Roux",
      "orcid": "0000-0001-5521-5445"
    },
    {
      "affs": [
        5,
        6
      ],
      "name": "Sean Wharton"
    },
    {
      "affs": [
        7
      ],
      "name": "Biykem Bozkurt",
      "orcid": "0000-0002-6362-0253"
    },
    {
      "affs": [
        2
      ],
      "name": "Daniel Ferraz de Campos Mazo",
      "orcid": "0000-0002-2164-2630"
    },
    {
      "affs": [
        8
      ],
      "name": "Jessica von Schlippenbach"
    },
    {
      "affs": [
        9
      ],
      "name": "Sandra González Maldonado",
      "orcid": "0009-0005-7723-7027"
    },
    {
      "affs": [
        2
      ],
      "name": "Samina Ajaz Hussain",
      "orcid": "0009-0002-4849-0363"
    },
    {
      "affs": [
        10
      ],
      "name": "Guy W. Neff",
      "orcid": "0009-0008-1408-2162"
    },
    {
      "affs": [
        11
      ],
      "name": "Yaneicy Gonzalez Rojas"
    },
    {
      "affs": [
        10
      ],
      "name": "Charles Smith"
    },
    {
      "affs": [
        2
      ],
      "name": "Ramy Younes",
      "orcid": "0000-0003-2302-5318"
    },
    {
      "affs": [
        12
      ],
      "name": "Arun Jayant Sanyal",
      "orcid": "0000-0001-8682-5748"
    },
    {
      "name": "on behalf of the SYNCHRONIZE-MASLD Investigators"
    },
    {
      "name": "Antonio O. Martin"
    },
    {
      "name": "Juan Manuel Pericàs",
      "orcid": "0000-0002-3645-3293"
    },
    {
      "affs": [
        13
      ],
      "name": "Mark Leibowitz"
    },
    {
      "affs": [
        14
      ],
      "name": "Douglas Scott Denham",
      "orcid": "0000-0002-3466-1208"
    },
    {
      "affs": [
        15
      ],
      "name": "Kevin Korenblat",
      "orcid": "0000-0002-7912-8191"
    },
    {
      "affs": [
        16
      ],
      "name": "Michael Herman"
    },
    {
      "affs": [
        17
      ],
      "name": "Shekhar Challa"
    },
    {
      "affs": [
        18
      ],
      "name": "Rasha Youssef"
    },
    {
      "affs": [
        19
      ],
      "name": "Masi Khaja"
    },
    {
      "affs": [
        20
      ],
      "name": "Apinya Vutikullird"
    },
    {
      "affs": [
        21
      ],
      "name": "Humberto Aguilar"
    },
    {
      "affs": [
        22
      ],
      "name": "Naga Chalasani",
      "orcid": "0000-0003-4082-3178"
    },
    {
      "affs": [
        23
      ],
      "name": "James Maher"
    },
    {
      "affs": [
        24
      ],
      "name": "Ronald Surowitz"
    },
    {
      "affs": [
        25
      ],
      "name": "Cassandra Steimle"
    },
    {
      "affs": [
        11
      ],
      "name": "Yaneicy G. Rojas"
    },
    {
      "affs": [
        26
      ],
      "name": "Antonio Sanchez"
    },
    {
      "affs": [
        27
      ],
      "name": "Ruth E. Kavcioglu"
    },
    {
      "affs": [
        28
      ],
      "name": "Julio C. Vijil"
    },
    {
      "affs": [
        29
      ],
      "name": "Robert Perry"
    },
    {
      "affs": [
        10
      ],
      "name": "Guy Neff"
    },
    {
      "affs": [
        30
      ],
      "name": "Martha G. Navarro"
    },
    {
      "affs": [
        31
      ],
      "name": "Omer Khalid"
    },
    {
      "affs": [
        32,
        33
      ],
      "name": "Rizwana Mohseni"
    },
    {
      "name": "Michael A. Zimmerman",
      "orcid": "0000-0002-1177-0911"
    },
    {
      "affs": [
        34
      ],
      "name": "Julie Vu"
    },
    {
      "affs": [
        35
      ],
      "name": "Gregg H. Lucksinger"
    },
    {
      "affs": [
        36
      ],
      "name": "Satish Iduru"
    },
    {
      "affs": [
        37
      ],
      "name": "Dmitry Shuster"
    },
    {
      "affs": [
        38
      ],
      "name": "Bruce Segal"
    },
    {
      "affs": [
        39
      ],
      "name": "Paul Hellstern"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/2sbrg22vde4fs.bib",
  "cited_by": 18,
  "doi": "10.1038/s41591-026-04479-3",
  "fulltext_url": null,
  "id": "2sbrg22vde4fs",
  "issns": [
    "1078-8956",
    "1546-170X",
    "1744-7933"
  ],
  "landing_url": "https://doi.org/10.1038/s41591-026-04479-3",
  "language": "en",
  "licence": "CC-BY",
  "licence_label": "CC BY",
  "licence_source": "journal",
  "licence_url": "https://creativecommons.org/licenses/by/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "openalex",
      "2713|Liver Disease Diagnosis and Treatment"
    ]
  ],
  "openalex": "W7163822045",
  "pdf_url": "https://www.nature.com/articles/s41591-026-04479-3.pdf",
  "pmcid": "PMC13472939",
  "pmid": "42252333",
  "published": "2026-06-07",
  "publisher": "Nature Portfolio",
  "ris": "https://research.draconitic.com/paper/2sbrg22vde4fs.ris",
  "sources": [
    {
      "first_seen": "2026-10-30T13:26:54Z",
      "native_id": "W7163822045",
      "source": "openalex",
      "url": "https://doi.org/10.1038/s41591-026-04479-3"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "openalex:2713|Liver Disease Diagnosis and Treatment",
      "subfield": "epidemiology-public-health"
    }
  ],
  "title": "Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trial",
  "title_text": "Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trial",
  "type": "peer-reviewed",
  "updated_at": "2026-11-06T13:20:38Z",
  "url": "https://research.draconitic.com/paper/2sbrg22vde4fs",
  "venue": "Nature Medicine",
  "versions": []
}